Free shipping on all orders over $ 500

Larotrectinib (LOXO-101)

Cat. No. M6151
Larotrectinib (LOXO-101) Structure

ARRY-470, larotrectinib

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 40  USD40 In stock
5mg USD 70  USD70 In stock
10mg USD 90  USD90 In stock
50mg USD 250  USD250 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: Larotrectinib (LOXO-101) was evaluated for off-target kinase enzyme inhibition against a panel of 226 non-TRK kinases at a compound concentration of 1,000 nM and ATP concentrations near the Km for each enzyme. LOXO-101 demonstrated greater than 50% inhibition for only one non-TRK kinase (TNK2 IC50 = 576 nM).

In vivo: A single dose (30 mg/kg) of LOXO-101 reduced tyrosine phosphorylation of TRKA and downstream signal transduction (pERK) in the tumor >80%. LOXO-101 was well tolerated up to 200 mg/kg/day for 14 d in this model.

Product Citations
Customer Product Validations & Biological Datas
Source Cancer Discov (2015). Figure 1. LOXO-101
Method MTS assay
Cell Lines CUTO-3.29 cells
Concentrations 100 nM
Incubation Time 2 h
Results pAKT was not inhibited in the CUTO-3.29 cells by LOXO-101 suggesting that TRK signaling is not AKT-dependent in this tumor.
Protocol (for reference only)
Cell Experiment
Cell lines KM12 cells
Preparation method Dose-dependent inhibition with LOXO-101 is demonstrated in three cancer cell line models of oncogenic TRK.
Concentrations 100 nM
Incubation time 24h
Animal Experiment
Animal models Athymic nude mice
Dosages 60 mg/kg
Administration oral gavage
Chemical Information
Molecular Weight 428.44
Formula C21H22F2N6O2
CAS Number 1223403-58-4
Solubility (25°C) DMSO 4.3 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Nagasubramanian R, et al. Pediatr Blood Cancer. Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.

[2] Doebele RC, et al. Cancer Discov. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Related Trk Products
Cyclotraxin B

Cyclotraxin B, a cyclic peptide, is a highly potent and selective TrkB inhibitor without altering the binding of BDNF.

Gambogic amide

Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK.

Protein kinase inhibitor 4

Protein kinase inhibitor 4 is a protein kinase inhibitor that inhibits TRK-A and ROS1 (IC50=3.0 nM and 104 nM respectively).


TRK-IN-22 is a TRK inhibitor.


TrkB-IN-1 is a potent and orally active TrkB agonist and has favorable PK properties.

Abmole Inhibitor Catalog

Keywords: Larotrectinib (LOXO-101), ARRY-470, larotrectinib supplier, Trk, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.